Summary
114.44 -0.57(-0.50%)05/16/2024
Illumina Inc (ILMN)
Illumina Inc (ILMN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -5.16 | -8.30 | -13.30 | -21.10 | -1.46 | -42.35 | -64.80 | 476.08 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 112.83 | |
| Open | 119.00 | |
| High | 119.43 | |
| Low | 112.81 | |
| Volume | 2,567,810 | |
| Change | -6.14 | |
| Change % | -5.16 | |
| Avg Volume (20 Days) | 1,290,824 | |
| Volume/Avg Volume (20 Days) Ratio | 1.99 | |
| 52 Week Range | 89.00 - 213.91 | |
| Price vs 52 Week High | -47.25% | |
| Price vs 52 Week Low | 26.78% | |
| Range | -5.18 | |
| Gap Up/Down | -0.40 | |
Fundamentals | ||
| Market Capitalization (Mln) | 18,226 | |
| EBIDTA | 345,000,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 4.2960 | |
| WallStreet Target Price | 150.96 | |
| Book Value | 36.0630 | |
| Earnings Per Share | -8.1500 | |
| EPS Estimate Current Quarter | 0.0400 | |
| EPS Estimate Next Quarter | 0.1500 | |
| EPS Estimate Current Year | 0.7100 | |
| EPS Estimate Next Year | 2.5500 | |
| Diluted EPS (TTM) | -8.1500 | |
| Revenues | ||
| Profit Marging | -0.2871 | |
| Operating Marging (TTM) | -0.0548 | |
| Return on asset (TTM) | -0.0050 | |
| Return on equity (TTM) | -0.2076 | |
| Revenue TTM | 4,493,000,192 | |
| Revenue per share TTM | 28.3920 | |
| Quarterly Revenue Growth (YOY) | -0.0100 | |
| Quarterly Earnings Growth (YOY) | -0.9650 | |
| Gross Profit (TTM) | 3,145,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 129.8701 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.5227 | |
| Revenue Enterprise Value | 4.7616 | |
| EBITDA Enterprise Value | -35.2733 | |
| Shares | ||
| Shares Outstanding | 159,300,000 | |
| Shares Float | 158,799,798 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 0.25 | |
| Institutions (%) | 97.55 | |
05/15 16:05 EST - prnewswire.com
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bernstein's 40th Annual Strategic Decisions Conference on May 29, 2024 Fireside chat at 6:00am Pacific Time (9:00am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bernstein's 40th Annual Strategic Decisions Conference on May 29, 2024 Fireside chat at 6:00am Pacific Time (9:00am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.
05/14 11:18 EST - seekingalpha.com
Illumina, Inc. (ILMN) RBC Capital Markets Global Healthcare (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) RBC Capital Markets Global Healthcare Call May 14, 2024 8:30 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Salli Schwartz - Investor Relations Conference Call Participants Conor McNamara - RBC Capital Markets Conor McNamara Good morning, everyone. Welcome to RBC Capital Markets 2024 Global Healthcare Conference.
Illumina, Inc. (ILMN) RBC Capital Markets Global Healthcare (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) RBC Capital Markets Global Healthcare Call May 14, 2024 8:30 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Salli Schwartz - Investor Relations Conference Call Participants Conor McNamara - RBC Capital Markets Conor McNamara Good morning, everyone. Welcome to RBC Capital Markets 2024 Global Healthcare Conference.
05/13 07:00 EST - businesswire.com
GRAIL to Host Capital Markets Day
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC announced today that it will host a virtual Capital Markets Day.
GRAIL to Host Capital Markets Day
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC announced today that it will host a virtual Capital Markets Day.
05/10 06:00 EST - investorplace.com
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.
05/06 18:28 EST - prnewswire.com
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
GRAIL to host Capital Markets Day on May 13, 2024 SAN DIEGO , May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was submitted to the SEC last December as required.
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
GRAIL to host Capital Markets Day on May 13, 2024 SAN DIEGO , May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was submitted to the SEC last December as required.
05/03 10:41 EST - zacks.com
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.
05/02 20:39 EST - seekingalpha.com
Illumina, Inc. (ILMN) Q1 2024 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q1 2024 Earnings Call Transcript May 2, 2024 5:00 PM ET Company Participants Salli Schwartz - Vice President, Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Joydeep Goswami - Advisor Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen David Westenberg - Piper Sandler Subha Nambi - Guggenheim Securities Sung Ji Nam - Scotiabank Tejas Savant - Morgan Stanley Mason Carrico - Stephens Rachel Vatnsdal - JPMorgan Patrick Donnelly - Citi Eve Burstein - Bernstein Research Conor McNamara - RBC Capital Markets Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.
Illumina, Inc. (ILMN) Q1 2024 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q1 2024 Earnings Call Transcript May 2, 2024 5:00 PM ET Company Participants Salli Schwartz - Vice President, Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Joydeep Goswami - Advisor Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen David Westenberg - Piper Sandler Subha Nambi - Guggenheim Securities Sung Ji Nam - Scotiabank Tejas Savant - Morgan Stanley Mason Carrico - Stephens Rachel Vatnsdal - JPMorgan Patrick Donnelly - Citi Eve Burstein - Bernstein Research Conor McNamara - RBC Capital Markets Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.
05/02 20:31 EST - zacks.com
Illumina (ILMN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Illumina (ILMN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
05/02 18:25 EST - reuters.com
Illumina reaffirms annual revenue forecast over continued sluggish demand
Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.
Illumina reaffirms annual revenue forecast over continued sluggish demand
Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.
05/02 16:05 EST - prnewswire.com
Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis) Core Illumina GAAP operating margin of 11.0% and non-GAAP operating margin of 20.6% for Q1 2024 Reiterating fiscal year 2024 Core Illumina revenue guidance that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin for fiscal year 2024 of approximately 20% Consolidated revenue of $1.08 billion for Q1 2024, down 1% from Q1 2023 (down 1% on a constant currency basis) GAAP diluted loss per share of ($0.79) for Q1 2024, compared to GAAP diluted earnings per share of $0.02 for Q1 2023 Non-GAAP diluted earnings per share of $0.09 for Q1 2024, compared to non-GAAP diluted earnings per share of $0.08 in Q1 2023 Illumina remains on track to divest GRAIL through either a sale or a capital markets transaction, with the goal of finalizing the terms of divestiture by the end of Q2 2024. In April, Illumina received approval of its divestment plan from the European Commission.
Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis) Core Illumina GAAP operating margin of 11.0% and non-GAAP operating margin of 20.6% for Q1 2024 Reiterating fiscal year 2024 Core Illumina revenue guidance that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin for fiscal year 2024 of approximately 20% Consolidated revenue of $1.08 billion for Q1 2024, down 1% from Q1 2023 (down 1% on a constant currency basis) GAAP diluted loss per share of ($0.79) for Q1 2024, compared to GAAP diluted earnings per share of $0.02 for Q1 2023 Non-GAAP diluted earnings per share of $0.09 for Q1 2024, compared to non-GAAP diluted earnings per share of $0.08 in Q1 2023 Illumina remains on track to divest GRAIL through either a sale or a capital markets transaction, with the goal of finalizing the terms of divestiture by the end of Q2 2024. In April, Illumina received approval of its divestment plan from the European Commission.
05/01 12:46 EST - zacks.com
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.
04/29 10:22 EST - zacks.com
Gear Up for Illumina (ILMN) Q1 Earnings: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Gear Up for Illumina (ILMN) Q1 Earnings: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
04/25 11:05 EST - zacks.com
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/19 13:15 EST - zacks.com
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
04/16 11:50 EST - youtube.com
2 Cheap Growth Stocks to Buy During 2Q
These undervalued stocks from the growth side of the Morningstar style box are among our analysts' favorites today. 00:00 Introduction 00: 31 Adobe ADBE 01:09 Illumina ILMN I'm Susan Dziubinski with Morningstar.
2 Cheap Growth Stocks to Buy During 2Q
These undervalued stocks from the growth side of the Morningstar style box are among our analysts' favorites today. 00:00 Introduction 00: 31 Adobe ADBE 01:09 Illumina ILMN I'm Susan Dziubinski with Morningstar.
04/12 09:00 EST - prnewswire.com
Illumina's planned divestment of GRAIL approved by the European Commission
SAN DIEGO , April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC). While this does not mean the method of divestment has been finalized, the company is pleased to reach an agreement with the EC on specific divestment options as it represents an important milestone in the process.
Illumina's planned divestment of GRAIL approved by the European Commission
SAN DIEGO , April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC). While this does not mean the method of divestment has been finalized, the company is pleased to reach an agreement with the EC on specific divestment options as it represents an important milestone in the process.
04/12 05:50 EST - reuters.com
EU approves Illumina's plan to divest cancer test maker Grail
The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker Grail , it said in a statement on Friday.
EU approves Illumina's plan to divest cancer test maker Grail
The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker Grail , it said in a statement on Friday.
04/09 16:33 EST - reuters.com
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.
04/09 16:05 EST - prnewswire.com
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO , April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO , April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.